Lovisenberg Diakonale Sykehus AS
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The Department of Infectious Diseases at Lovisenberg Diakonale Sykehus is evaluating apixaban as a stroke‑prevention strategy for patients with atrial fibrillation and advanced chronic kidney disease, including those on dialysis. The goal is to determine whether the medication can lower ischemic events without raising serious bleeding risks.
- Stroke prevention in high‑risk kidney patients
- Anticoagulation safety assessment
- Impact of dialysis status on outcomes
- Comparative effectiveness versus no anticoagulation
Findings from this work aim to guide clinicians in balancing clot‑prevention benefits against bleeding concerns in a vulnerable population.
Digestive System Diseases
Researchers are testing the novel oral agent ZED1227 to see if it can further relieve symptoms in individuals with celiac disease who continue to experience discomfort despite adhering to a gluten‑free diet. The study focuses on improving patient‑reported outcomes and intestinal healing.
- Symptom reduction on a gluten‑free regimen
- Assessment of mucosal recovery
- Evaluation of multiple dose levels
- Patient‑focused quality‑of‑life measures
Success could provide an additional therapeutic option for those whose disease remains active despite dietary control.
Neoplasms
The site is advancing precision medicine in oncology by offering access to commercially available, targeted therapies for patients whose tumors carry specific genomic or protein expression variants. The research tracks anti‑tumour activity and monitors toxicity to support personalized treatment pathways.
- Genomic profiling for drug selection
- Targeted therapy accessibility
- Toxicity and safety surveillance
- Real‑world effectiveness evaluation
This initiative seeks to improve outcomes for individuals with advanced malignancies through tailored therapeutic choices.
Bacterial Infections and Mycoses
In patients with suspected community‑acquired sepsis, investigators are comparing a combination of narrow‑spectrum β‑lactam antibiotics and an aminoglycoside against broad‑spectrum regimens to assess safety and non‑inferiority. The trial aims to identify effective early‑treatment options that may reduce unnecessary antibiotic exposure.
- Early antimicrobial strategy evaluation
- Narrow‑spectrum efficacy comparison
- Safety and adverse‑event monitoring
- Antibiotic stewardship implications
Results could influence guidelines for initial sepsis management and promote more judicious use of broad‑spectrum agents.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 8 therapeutic areas and 15 of 46 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 44 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Oslo University Hospital HF1active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Oslo University Hospital HF3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 112 other sites in Norway
Therapeutic Area Benchmark — Norway
Select a therapeutic area to compare against other sites in Norway.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Norway
Market Share
Country: Norway
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Lovisenberg Diakonale Sykehus AS
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability, and Pharmacodynamics of AZD4831 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis | AstraZeneca AB | Phase II | Not Recruiting | Dec 2022 | Apr 2024 |
IMP list
lock Showing 1 of 46 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Alectinib Hydrochloride | 1 | Unknown | 2021-04-01 | 2021-04-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.